Multiple Myeloma: Planning a Continuum of Care in 2020

EP. 1: Frontline Triplet Therapies in Multiple Myeloma

July 17th 2020

EP. 2: Tolerability of Triplet Therapy in Multiple Myeloma

July 17th 2020

EP. 3: Transplant-Ineligible Multiple Myeloma

July 17th 2020

EP. 4: Treating Transplant-Eligible and -Ineligible MM

July 17th 2020

EP. 5: The Role of Transplant in Multiple Myeloma

July 17th 2020

EP. 6: MRD Monitoring in Multiple Myeloma

July 17th 2020

EP. 7: Maintenance Therapy Approaches in Multiple Myeloma

July 17th 2020

EP. 8: Management of Relapsed/Refractory Multiple Myeloma

July 17th 2020

EP. 9: Daratumumab With Carfilzomib in Frontline Multiple Myeloma

July 17th 2020

EP. 10: Lenalidomide-Refractory Multiple Myeloma

July 17th 2020

EP. 11: BOSTON Study; SVd in Relapsed/Refractory Multiple Myeloma

July 17th 2020

EP. 12: BELLINI Trial; Venetoclax-Vd in Multiple Myeloma

July 17th 2020

EP. 13: BCMA-Targeted Therapies in Multiple Myeloma

July 17th 2020

EP. 14: Using Antibody-Drug Conjugates in Multiple Myeloma

July 17th 2020

EP. 15: Development of CAR T Cells in Multiple Myeloma

July 17th 2020

EP. 16: Differentiating among CAR T Products for Multiple Myeloma

July 17th 2020

EP. 17: Bispecific Antibodies for Multiple Myeloma

July 17th 2020

EP. 18: Future of BCMA-Targeted Therapies in Multiple Myeloma

July 17th 2020